Completed PHASE3 INTERVENTIONAL 2-arm NCT00030901

S9917, Selenium in Preventing Cancer in Patients With Neoplasia of the Prostate

L-Selenium-Based Chemoprevention Of Prostate Cancer Among Men With High Grade Prostatic Intraepithelial Neoplasia

Sponsor: Cancer and Leukemia Group B

Conditions Precancerous/Nonmalignant Condition Prostate Cancer

Interventions L-selenomethionine L-selenomethionine placebo

Updated 7 times since 2017 Last updated: Jan 2, 2013 Started: Feb 29, 2000 Primary completion: Nov 30, 2011 Completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Precancerous/Nonmalignant Condition and Prostate Cancer, this trial is completed. The trial is conducted by Cancer and Leukemia Group B and has accumulated 7 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
May 2023 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — May 2023 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Feb 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cancer and Leukemia Group B
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.